DOYLESTOWN, PA - April 10, 2003 - The Quigley Corporation (Nasdaq: QGLY),
marketer and distributor of COLD-EEZE®, the nation's leading pharmacist
recommended over-the-counter zinc cold remedy, announced today the introduction
of a sore throat lollipop under its all-new KIDZ-EEZETM banner. Featuring
pectin to soothe sore throats, the KIDZ-EEZE Sore Throat Pop will begin
shipping to retail in August 2003. This introduction marks the first time that
The Quigley Corporation has developed a product specifically addressing
children's sore throats.
The KIDZ-EEZE Sore Throat Pop, containing 20 mg of pectin, is designed to
soothe sore throats, one of the primary symptoms of the common cold. The pops,
which also include 30 mg of Vitamin C and 4.4 mg of Zinc Gluconate, will be
available in a random assortment of four great-tasting flavors: cherry, grape,
orange, and bubblegum.
"Combined with the recent announcement of our COLD-EEZE Zinc Gluconate Cold
Remedy Nasal Spray, the debut of the KIDZ-EEZE Sore Throat Pop solidifies our
position as a leader in the cold care category," said Guy J. Quigley, Chairman,
President and Chief Executive Officer of The Quigley Corporation. "We are
confident that this newest offering will appeal to parents and kids, while
satisfying our retail customers with new, related Quigley products."
Packaging for the KIDZ-EEZE Sore Throat Pops will leverage the popularity of
the COLD-EEZE brand while also clearly displaying the new KIDZ-EEZE logo. The
launch of the pops will be supported with an integrated marketing campaign,
including advertising, public relations and in-store support.
About The Quigley Corporation
The Quigley Corporation (NASDAQ: QGLY) (www.quigleyco.com) is a leading
developer and marketer of diversified health products including the Cold-Eeze®
family of patented zinc gluconate glycine (ZIGG(tm)) lozenges, gums and sugar
free tablets. Cold-Eeze is the only (ZIGG(tm)) lozenge proven in two
double-blind studies to reduce the duration of the common cold from 7.6 to 4.4
days or by 42%. In addition to Over-The-Counter (OTC) products, the Company
has formed Quigley Pharma Inc. (www.QuigleyPharma.com), a wholly owned ethical
pharmaceutical subsidiary, to introduce a line of patented prescription drugs.
The Quigley Corporation's customers include leading national wholesalers and
distributors, as well as independent and chain food, drug and mass merchandise
stores and pharmacies.
Additional information about The Quigley Corporation is available on its Web
site at www.quigleyco.com.
Certain statements in this press release are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995 and
involve known and unknown risk, uncertainties and other factors that may cause
the Company's actual results, performance or achievements to be materially
different from the results, performance or achievements expressed or implied by
the forward-looking statement. Factors that impact such forward-looking
statements include, among others, changes in worldwide general economic
conditions, changes in interest rates, government regulations, and worldwide
competition.
